Condition
Mesothelioma|Adenocarcinoma of Lung|Pancreatic Neoplasms
Estimated Enrollment: 55
Age Group: 18 Years to 99 Years (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment
Study ID Numbers: 110160|11-C-0160
Study First Received: May 27, 2011
Last Updated: April 20, 2017
Estimated Primary Completion Date: August 3, 2016
Primary Outcome Measures:
Objective response rate stratified by tumor type|SS1P antibody formation|Grade and description of adverse events|determine RP2D in drug lot FIL129J01|Overall survival|Progression-free survival|Duration of response
Sponsors and Collaborators:
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Website Link: https://ClinicalTrials.gov/show/NCT01362790
